Intravitreal Injections in Huddersfield
Consultant-led intravitreal injection therapy for wet age-related macular degeneration, diabetic macular oedema, retinal vein occlusion, and other sight-threatening retinal conditions. NICE-approved anti-VEGF treatments delivered with precision and care.
Affiliations & As Seen In
Read About Our Happy Patients
What a great experience! Very reassuring and I am very grateful for the consultation from Dr Musa he was so helpful in helping me make a decision to proceed to having eye correction surgery. I have the upmost confidence in him and the team at the Eye Doctor Clinic, Huddersfield.
Lozza 747I had implants with Dr Musa ten years ago. It was the best thing I've ever done. They are brilliant. My sight both near and distant was very poor but since the op I've had no glasses no lenses and my sight has been super. It remains really good to this day. Thank you Dr Musa. Brilliant consultations and treatment for glaucoma since.
Kay FitbitI can highly recommend the Eye Doctor Clinic, and I am so pleased I went there. Dr Musa, Gemma and Jess are lovely. They are very knowledgeable and were able to answer all my questions. My vision following surgery is great, and not having to wear glasses is fantastic.
Carol PeelWhat Are Intravitreal Injections?
Intravitreal injections deliver medication directly into the vitreous — the gel-filled cavity inside the eye. By bypassing the bloodstream, the drug reaches the retina at high concentration and with rapid effect, making this the most effective route of administration for treating macular and retinal diseases.
The most widely used agents are anti-VEGF (anti-vascular endothelial growth factor) drugs. VEGF is a protein that drives the growth of abnormal, leaky blood vessels beneath the retina — the underlying mechanism in wet AMD, diabetic macular oedema, and retinal vein occlusion. By blocking VEGF, these medications halt abnormal vessel growth, reduce macular fluid, and in many cases restore a meaningful degree of central vision.
Anti-VEGF therapy has transformed the outlook for patients with these conditions over the past two decades. Where previously wet AMD almost invariably led to severe central vision loss, the majority of patients treated promptly with intravitreal injections now maintain or improve their vision.
Injections at a Glance
- Drug class: Anti-VEGF agents
- NICE approved: Aflibercept, ranibizumab, faricimab, brolucizumab
- Anaesthesia: Topical drops only
- Procedure time: ~5 minutes
- Appointment: 20–30 minutes total
- Setting: Outpatient clinic
- Loading phase: Typically 3 monthly injections
- Maintenance: Treat-and-extend or PRN protocol
Conditions Treated
Wet Age-Related Macular Degeneration (Wet AMD)
Abnormal blood vessels grow beneath the macula and leak fluid, causing rapid, progressive central vision loss. Anti-VEGF injections are the first-line NICE-approved treatment and can stabilise or improve vision when started promptly.
Diabetic Macular Oedema (DMO)
Fluid accumulates in the central retina as a consequence of diabetic retinopathy, causing blurred and distorted central vision. Anti-VEGF therapy is now the preferred treatment for centre-involving DMO, often combined with laser as required.
Retinal Vein Occlusion (RVO)
A blocked retinal vein — either branch (BRVO) or central (CRVO) — causes macular oedema and sudden visual loss. Anti-VEGF injections treat the oedema and improve visual acuity in the majority of patients.
Myopic Choroidal Neovascularisation
Abnormal new blood vessels can develop beneath the retina in highly myopic eyes, threatening central vision. Anti-VEGF injections are highly effective for this condition and typically require fewer injections than wet AMD.
Anti-VEGF Medicines Used
All drugs used at The Eye Doctor are NICE-approved for their respective indications. Your consultant will recommend the most appropriate agent based on your diagnosis, disease activity, and individual circumstances.
Aflibercept (Eylea)
NICE-approved for wet AMD, DMO, and RVO. Binds VEGF-A, VEGF-B, and PlGF. After a loading phase, intervals can be extended to every 8 weeks or beyond.
Ranibizumab (Lucentis)
NICE-approved for wet AMD, DMO, and RVO. A humanised antibody fragment that binds all isoforms of VEGF-A. Monthly or treat-and-extend dosing.
Faricimab (Vabysmo)
The newest NICE-approved agent for wet AMD and DMO. Dual inhibitor of VEGF-A and Angiopoietin-2. Many patients can be extended to every 16 weeks after loading.
Brolucizumab (Beovu)
NICE-approved for wet AMD. A single-chain antibody fragment with high molar concentration. Suitable patients may be treated every 12 weeks following loading.
What to Expect
Preparation
The eye is cleaned with povidone-iodine antiseptic solution to minimise the risk of infection. A sterile drape and eyelid speculum are applied to keep the eye open and maintain a clean field throughout.
Anaesthetic Drops
Anaesthetic drops numb the surface of the eye completely. The injection itself is not painful. Some patients feel brief pressure during the procedure, which resolves immediately.
The Injection
A very fine needle (typically 30-gauge) is used to deliver the medication directly into the vitreous cavity through the pars plana, 3.5–4 mm from the limbus. The procedure itself takes only a few seconds.
Post-Injection Check
Intraocular pressure is checked briefly after the injection. The eye is inspected to confirm the medication has been delivered correctly. You may notice floaters or a small red patch on the white of the eye — both are normal and temporary.
Aftercare Instructions
You will be given antibiotic drops to use for several days following the injection. You should avoid rubbing the eye, swimming, and wearing eye make-up for 48 hours. Contact the clinic immediately if you experience increasing pain, marked redness, or sudden vision loss.
Follow-Up & Repeat Injections
Most conditions require a series of injections. The frequency is determined by your response — using treat-and-extend or pro re nata (PRN) protocols — with regular OCT imaging to monitor disease activity and guide retreatment decisions.
Why Choose The Eye Doctor
Intravitreal Injection FAQs
An intravitreal injection delivers medication directly into the vitreous cavity — the gel-filled space inside the eye, in front of the retina. This allows the drug to reach the retina at high concentration without needing to pass through the bloodstream. The most commonly used agents are anti-VEGF drugs, which block the protein responsible for abnormal blood vessel growth and fluid leakage in conditions such as wet AMD and diabetic macular oedema.
Most patients find the procedure surprisingly comfortable. Anaesthetic drops numb the surface of the eye before the injection. You may feel a brief sense of pressure during the injection itself, but this passes immediately. Some patients experience mild discomfort or irritation in the hours following the procedure, which settles quickly.
The injection itself takes only a few seconds. Including preparation, anaesthesia, the injection, and the post-procedure check, most appointments are completed within 20–30 minutes. You will be able to go home the same day.
The number of injections varies depending on the condition being treated and your individual response. Wet AMD and DMO typically require an initial loading phase of three monthly injections, followed by maintenance injections at intervals determined by disease activity — usually every 6–16 weeks using a treat-and-extend or pro re nata (PRN) protocol. Your specialist will review your OCT scans at every visit and adjust your treatment schedule accordingly.
The main anti-VEGF agents used in the UK are aflibercept (Eylea), ranibizumab (Lucentis), faricimab (Vabysmo), and brolucizumab (Beovu). All are NICE-approved for specific indications. Your consultant will recommend the most appropriate drug based on your diagnosis, disease activity, and the current clinical evidence.
Mr Murtuza Mookhtiar
MBChB · FRCOphth
Consultant Ophthalmic Surgeon, Cataract & Retinal Specialist
Mr Murtuza Mookhtiar is a Consultant Ophthalmic Surgeon with a specialist interest in vitreoretinal surgery and cataract surgery. He manages a wide range of complex retinal conditions including retinal detachment, epiretinal membrane, macular hole, and vitreous floaters. Mr Mookhtiar combines precise surgical technique with a compassionate approach, ensuring patients receive the highest standard of care throughout their treatment journey.
Mrs Farhat Butt
MBChB · FRCOphth
Consultant Ophthalmologist, Medical Retina & Uveitis
Mrs Farhat Butt is a Consultant Ophthalmologist specialising in medical retina and uveitis. She has extensive experience in the diagnosis and management of sight-threatening conditions including wet age-related macular degeneration, diabetic macular oedema, retinal vein occlusion, and complex uveitis. Mrs Butt is highly experienced in intravitreal injection therapy and provides expert, patient-centred care for some of the most challenging retinal and inflammatory eye conditions.
Meet the Team
Where to Find Us
Three convenient locations across West Yorkshire. Visit us for consultations, diagnostics, and treatments.
Bolton
136 – 140 Newport St
Bolton, Greater Manchester
BL3 6AB
Huddersfield
Woodlands, 4 Longbow Close
Huddersfield, HD2 1GQ
Concerned About Your Macular Health?
Early treatment gives the best chance of preserving your central vision. Call +44 1484 627779 or book a consultation with our retinal specialists today.
